Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Supriya Kohli

Neurology Cookeville, TN Medical Doctor

NPI 1194019570 CMS profile 1359654

1 Medical Center Blvd, Suite 103, Cookeville, TN 38501

Open in the dashboard

General payments

$24,919

1,319 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Supriya Kohli of Cookeville, TN is reported in the CMS Open Payments database as having received $24,919 across 1,319 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 85th percentile of Neurology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $4,195 193
2024 General $4,566 215
2023 General $3,164 171
2022 General $3,838 217
2021 General $3,779 221
2020 General $2,470 141
2019 General $2,908 161

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Supriya Kohli
  • Neurology median
  • Middle half of Neurology
  • National median

In program year 2025, general payments to Supriya Kohli were reported at $4,195. Among 11,022 Neurology profiles paid that year, the median was $457 and the middle half received between $118 and $2,344.

Show as a table
Year Supriya Kohli Neurology median Middle half National median
2019 $2,908 $474 $118–$2,177 $163
2020 $2,470 $367 $82–$2,309 $114
2021 $3,779 $438 $104–$2,547 $132
2022 $3,838 $442 $103–$2,388 $149
2023 $3,164 $464 $119–$2,312 $160
2024 $4,566 $468 $119–$2,323 $164
2025 $4,195 $457 $118–$2,344 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. UCB, Inc. $3,239 138 payments
  2. AbbVie, Inc. $2,809 166 payments
  3. Amgen Inc. $1,404 52 payments
  4. SK Life Science, Inc. $1,181 42 payments
  5. Pfizer Inc. $1,060 71 payments
  6. Novartis Pharmaceuticals Corporation $1,016 51 payments
  7. Teva Pharmaceuticals USA, Inc. $950 61 payments
  8. Lilly USA, LLC $929 51 payments
  9. Supernus Pharmaceuticals, Inc. $920 66 payments
  10. US WorldMeds, LLC $915 44 payments
  11. Other $10,496 577 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $24,732 1,306 payments
  2. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $110 8 payments
  3. Education $77 5 payments
Products named General payments · program years 2019–2025
  1. UBRELVY $1,595 87 payments
  2. Briviact $1,570 72 payments
  3. AIMOVIG $1,481 62 payments
  4. QULIPTA $1,031 71 payments
  5. NURTEC ODT Pain $887 61 payments
  6. Epidiolex $868 34 payments
  7. NURTEC ODT Primary Care $864 68 payments
  8. VYVGART $809 41 payments
  9. ZAVZPRET $776 52 payments
  10. Vimpat $770 30 payments
  11. Other $15,506 843 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 58 drugs

Part D claims

5,793

Median for Neurology: 833

Drug cost

$834,124

Median for Neurology: $202,670

Branded share of claims

23.5%

Median for Neurology: 25.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Nuplazid Pimavanserin Tartrate Brand 36 $179,432
Ubrelvy Ubrogepant Brand 87 $101,567
Nurtec Odt Rimegepant Sulfate Brand 54 $81,397
Qulipta Atogepant Brand 58 $70,834
Emgality Pen Galcanezumab-Gnlm Brand 91 $68,436
Briviact Brivaracetam Brand 44 $67,533
Aimovig Autoinjector Erenumab-Aooe Brand 62 $57,688
Xcopri Cenobamate Brand 31 $38,310
Gocovri Amantadine Hcl Brand 11 $18,631
Keppra Xr Levetiracetam Brand 12 $18,391

The 10 drugs with the highest cost, of 58 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 13,695 Part D prescribers listed as Neurology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 14 billing codes

Paid by Medicare

$65,607

Medicare's payments for the services billed

Medicare patients

345

Average age 74

Services billed

3,953

209 women, 136 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 56%
Depression 35%
Ischemic heart disease 34%
Diabetes 32%
Atrial fibrillation 24%
Chronic kidney disease 24%
Alzheimer's or dementia 21%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 37 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Briviact
$530 44 —
Gocovri
$461 11 —
Rystiggo
$350 — —
QULIPTA
$277 58 —
VYVGART
$238 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 37 with Patron

Records

1,319 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Neurology in Tennessee

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record